Overview

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
0
Participant gender:
All
Summary
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Solvay Pharmaceuticals
Criteria
Inclusion Criteria:

- Patients who have completed S308.3.001 trial

Exclusion Criteria:

- Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at
end of the maintenance phase (visit M6, week 24) of study S308.3.001